•      GIST is the most common mesenchymal neoplasm of gastrointestinal tract. Most patient present in 5^th to 7^th decade as abdominal mass.They originates from gastrointestinal pacemaker cells are characterized by over expression of tyrosine kinase receptor KIT. Prognostic factor for GIST are tumor size and mitotic rate. (1). Surgery is the standard treatment for primary resectable GIST.(2). Development of tyrosine kinase inhibitor has changed the management of unresectable malignant cases. New tyrosine kinase inhibitor, imatinib mesylate which inhibit c–kit receptor is highly effective against gist.(3)